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Abstract
Background: Presently melanoma still lacks adequate treatment options for metastatic disease. While melanoma is
exceptionally challenging to standard regimens, it is suited for treatment with immunotherapy based on its
immunogenicity. Since treatment-related skin depigmentation is considered a favourable prognostic sign during melanoma
intervention, we here aimed at the reverse approach of directly inducing vitiligo as a shortcut to effective anti-melanoma
immunity.
Methodology and Principal Findings: We developed an effective and simple to use form of immunotherapy by combining
the topical skin-bleaching agent monobenzone with immune-stimulatory imiquimod cream and cytosine-guanine
oligodeoxynucleotides (CpG) injections (MIC therapy). This powerful new approach promptly induced a melanoma antigen-
specific immune response, which abolished subcutaneous B16.F10 melanoma growth in up to 85% of C57BL/6 mice.
Importantly, this regimen induced over 100 days of tumor-free survival in up to 60% of the mice, and forcefully suppressed
tumor growth upon re-challenge either 65- or 165 days after MIC treatment cessation.
Conclusions: MIC therapy is effective in eradicating melanoma, by vigilantly incorporating NK-, B- and T cells in its
therapeutic effect. Based on these results, the MIC regimen presents a high-yield, low-cost and simple therapy, readily
applicable in the clinic.
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Introduction
Melanoma patients could benefit greatly from immunotherapy,
since melanoma is one of the most immunogenic tumors [1] and
metastatic disease responds poorly to conventional therapy, such
as irradiation and chemotherapy [2]. Cancer immunotherapy
underwent considerable progress in recent years, since the first
promising results of adjuvant immune stimulation using interfer-
on-a (IFN-a) and interleukin-2 (IL-2) [3–6]. Recent immunother-
apeutic vaccination strategies have appeared moderately effective
in achieving superior clinical results than standard interventions
[7–9]. Nonetheless, studies using the toll-like receptor (TLR)
ligand cytosine-guanine oligodeoxynucleotides (CpG) as a TLR9
agonist or imiquimod as a TLR7 agonist in the melanoma setting
[10–17], have shown encouraging results. Successful melanoma
immunotherapy can lead to treatment-related vitiligo-like leuko-
derma as an autoimmune side-effect [18], which is considered an
encouraging prognostic sign [19,20]. Therefore, as a reverse
approach, we here investigated the active induction of vitiligo as
an immunotherapy approach for melanoma treatment.
Skin contact with phenols or catechols, such as the mono-
benzylether of hydroquinone (MBEH or monobenzone), induces
depigmentation in susceptible individuals upon occupational
exposure, which is clinically and histologically indistinguishable
from vitiligo vulgaris [21–24]. Monobenzone is the most potent
skin depigmenting agent [21], discovered by Oliver et al. in 1939
[23]. In healthy individuals who have applied it to initially lighten
their skin tone it is known to induce vitiligo vulgaris [25–27].
Moreover, it has been used in a 20% cream for patients with
vitiligo universalis to induce complete depigmentation [27]. The
skin depigmentation spreads to distant sites unexposed to
monobenzone, indicating that monobenzone induces a progressive
systemic reaction against melanocytes, by acting as a skin sensitizer
[26,28,29]. Monobenzone specifically interacts with tyrosinase
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[21,30], the key enzyme in melanocyte pigment synthesis, and
forms quinone-haptens to the tyrosinase protein [31]. Quinone
metabolites of phenols or catechols have been shown to induce
extensive depigmentation in vivo [32,33] depending on the
enzymatic conversion by tyrosinase, and covalent binding as a
hapten to proteins [30,31].
Since we have previously shown that vitiligo vulgaris is mediated
by melanocyte antigen-specific CD8+ T cells [34], we postulate
that monobenzone by its selective interaction with melanocytes,
induces melanocyte-specific autoimmunity. In this report we
combined the topical skin-bleaching agent monobenzone with
immune-stimulating TLR7-agonist imiquimod and the TLR9-
agonist CpG [35,36], designated as MIC-treatment. This
combination proved to provoke a robust melanocyte antigen-
specific autoimmune response in C57BL/6 wildtype mice. This
activated response effectively abolished the growth of subcutane-
ous B16.F10 melanoma. Importantly, the therapeutic effect was
found in up to 85% of the mice, while it also mediated over 100
day tumor-free survival in 60% of the mice on average. Innate and
adaptive immunity cooperated in the observed therapeutic effect.
Our MIC therapy namely induced a melanocyte antigen-specific
CD8+ T cell response, a B16-specific serum IgG response and a
sustained NK cell expansion. Furthermore, the MIC treatment
conferred melanocyte antigen-specific CD8+ T cell-mediated
immunological memory that forcibly suppressed secondary tumor
growth. Our data establish the MIC therapy as an effective new
regimen in the field of melanoma immunotherapy.
Results
Expansion and activation of melanoma-reactive CD8+ T
cells and NK cells in response to monobenzone,
imiquimod and CpG treatment of subcutaneous B16.F10
melanoma
To characterize the in vivo immune response induced by
monobenzone and the immunostimulatory adjuvants CpG and
imiquimod against the highly aggressive and poorly immunogenic
B16.F10 melanoma, we inoculated C57BL/6 wildtype mice with
2.56103 B16.F10 cells subcutaneously in the right flank at day 0
(n = 5 mice/group), and from day 2 treated these mice with
monobenzone alone, the immunostimulatory adjuvants CpG and
imiquimod combined (CI) or monobenzone with imiquimod and
CpG (MIC). Importantly, tumors were injected in the flank, while
topical applications of monobenzone and imiquimod were
selectively applied on the shaved abdomen of the mice; CpG
was injected peritumorally. On treatment day 18, mice were
sacrificed and splenocytes were ex vivo tested for their specific
recognition of B16.F10 melanoma. Syngeneic EL4 mouse
thymoma cells were used as control.
As shown in figure 1A (left panel), MIC-treated mice showed
significantly elevated percentages of CD8+ T cells producing
TNF-a upon recognition of B16.F10 cells in vitro, as compared to
untreated mice. CD8+ T cells from MIC-treated mice did not
react to with the EL-4 control tumor cells, indicating the
melanoma specificity of the T cell response. This T cell activation,
albeit at a lower level, was also found in mice that were treated
with monobenzone alone, while CI-treated mice did not show
specific T cell reactivity against B16.F10 cells. Additionally, when
B16.F10 target cells were interferon-c (IFN-c)-primed to raise their
surface class-I expression (figure 1C), making them an optimal
CD8+ T cell target, more CD8+ T cell activation was seen in the
MIC-treated mice (figure 1A, right panel). The IFN-c primed
melanoma cells also evoked T cell activation in the CI-treated
mice, while T cell activation was not detected in the untreated-
and monobenzone-treated mice. The CD4+ T cell population did
not display any significant responses (data not shown).
NK cell activity against B16.F10 melanoma cells was found in
all treated mice as well as in untreated mice, as illustrated by TNF-
a and IFN-c production upon co-culture (figure 1B). These NK
cells did not react with EL4 control cells, illustrating their
melanoma-specific reactivity. However, NK cell activation was
significantly increased in MIC-treated mice as compared to
untreated mice, as indicated by the production of both TNF-a
and IFN-c. The other treatments did not enhance NK cell activity
against B16.F10 cells, except for the increased IFN-c production
by NK cells from CI-treated mice.
Taken together, these ex vivo analyses demonstrate that MIC-
and to a lesser extent CI-treatment induced the activation of TNF-
a-producing melanoma reactive CD8+ T cells. Furthermore, T
cells induced by the MIC treatment were also able to recognize
non-IFN-c-primed, poorly immunogenic melanoma cells. This
indicates that the MIC treatment generates a significant
melanoma-reactive CD8+ T cell population with elevated
functional avidity. Moreover, the MIC regimen significantly
increased NK-cell melanoma-reactivity in vivo.
Melanoma-reactive IgG response in MIC-treated mice
To further characterize the extent of the melanoma-specific
immune activation induced by the MIC treatment, we investigated
the formation of a melanoma-reactive antibody response. Of the
mice described in figure 1, peripheral blood serum was obtained
on day 18 of sacrifice. B16.F10 melanoma cells were permeabi-
lized and binding of serum IgG-, IgM-and IgA was determined.
Permeabilized EL4 thymoma cells were included as controls. As
shown in figure 2, only the MIC-treated mice showed significant
levels of melanoma-reactive serum IgG antibodies, whereas no
IgG binding to melanoma cells was found in monobenzone- and
CI-treated mice. Mice from all tested groups displayed compara-
ble background reactivity to EL4 thymoma cells, illustrating the
melanoma-specificity of the IgG-reactivity. IgG binding to intact,
unpermeabilized melanoma cells was negligible (data not shown).
Melanoma-reactive IgA was not detected and IgM did not show
any significant differences between groups (data not shown). The
melanoma-reactive IgG response induced by the MIC treatment in
vivo indicates the involvement of a concurrent B cell response
alongside the melanoma antigen-specific T cell activation found in
the MIC-treated mice.
MIC treatment inhibits growth of subcutaneous B16.F10
melanoma
To determine whether the melanoma antigen-specific immune
responses described above were able to eradicate B16.F10
melanoma in vivo, we treated mice bearing subcutaneous
melanoma and performed a long-term follow-up (figure 3A). On
day 0, C57BL/6 wildtype mice were inoculated subcutaneously
with 2.56103 B16.F10 melanoma cells. Treatments were started
on day 2, and continued for 33 days. Mice were either left
untreated, treated with the individual treatment components
monobenzone, CpG or imiquimod, or with CI- or MIC-treatment
regimens and tumor growth was monitored (figure 3A, n = 7 per
group). All untreated mice showed tumor development (TD)
around day 10, and none of these mice experienced a 200-day
tumor-free survival (TFS). In contrast, in 85% of mice treated with
MIC therapy the tumor did not grow during the treatment period
(figure 3A lower right panel). Only one mouse did not respond to the
MIC treatment and experienced a (delayed) tumor outgrowth
during the treatment period, while all other mice remained tumor-
free. 10 days after treatment cessation at day 35, two additional
MIC Therapy for Melanoma
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MIC-treated mice developed a melanoma. These animals were
directly sacrificed for analysis without monitoring their tumor
growth kinetics. This illustrates that MIC treatment effectively
suppressed melanoma growth in these two mice during treatment,
and that MIC therapy actively induces anti-tumor reactivity
without merely preventing tumor implantation. Ultimately, the
Figure 1. MIC treatment of subcutaneous B16.F10 melanoma induced melanoma-reactive CD8+ T cells and -NK cells in vivo.
Splenocytes were tested for their ex vivo activation upon co-culture with B16.F10 melanoma or EL4 thymoma control cells (n = 5 mice per group). A,
Left panel: CD8+ T cells from monobenzone- and MIC-treated mice showed significant TNF-a production upon co-culture with melanoma cells (black
bars; p,0.05 and p,0.003 respectively). In contrast, CD8+ T cells from CI-treated mice did not display significant TNF-a production upon melanoma
cell co-culture (non significant difference: ns). Right panel: To identify CD8+ T cell activation upon co-culture with immunogenic melanoma cells with
high MHC class-I expression, co-cultures with IFN-c primed B16.F10 cells were included (dashed bars). Under these conditions, CI-treated mice showed
significant TNF-a production as compared to untreated mice (p,0.03). The MIC-treated mice showed even more TNF-a production as in the non-IFN-
c-primed stimulation shown in the left panel. Monobenzone-treated and untreated mice did not display this increased T cell activation upon
splenocyte co-culture with IFN-c primed melanoma cells. T cell activation upon splenocyte co-culture with syngeneic EL4 thymoma control cells
showed comparable background levels in all groups (white bars). B, Left panel: Only NK cells from MIC-treated mice showed significantly increased
TNF-a production upon co-culture with melanoma cells (p,0.008). Right panel: Elevated production of IFN-c was found in NK cells from CI- and MIC-
treated mice in response to co-culture with melanoma cells (p,0.02 and p,0.02 respectively). TNF-a and IFN-c production by NK cells was
comparable in all groups upon co-culture with EL4 control cells. For the statistical analysis of the in vivo tumor growth kinetics of the treatments
depicted in this figure, see table 1 (‘‘Exp. 2’’). C, B16.F10 melanoma cells upregulate their surface MHC class-I expression upon IFN-c exposure. While
IFN-c-unexposed melanoma cells express very low levels of surface MHC class-I (dashed line), priming of these cells with 1000 U/ml IFN-c restores
their surface expression of MHC class-I (black line). Control incubations of IFN-c-primed melanoma cells with only the IgG2a-detecting secondary
antibody were negative (grey line).
doi:10.1371/journal.pone.0010626.g001
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remaining 57% of the MIC-treated mice experienced tumor-free
survival for more than 200 days. The individual treatment
components monobenzone, CpG or imiquimod all mediated a
certain degree of tumor growth delay, resulting in suppression of
melanoma outgrowth in these groups. Furthermore, the combi-
nation of CpG and imiquimod acted synergistically in delaying
melanoma outgrowth and inducing tumor-free survival. The
survival data are summarized in figure 3B, showing the long-term
tumor-free survival data of the different treatments. The
therapeutic effect of the MIC treatment was found in four
independent in vivo experiments, which all showed significant
inhibition of tumor growth (table 1).
To investigate whether long-term surviving MIC-treated mice
developed protective immunological memory, MIC-treated 100-
and 200-day surviving mice from two independent experiments
were challenged with B16.F10 melanoma cells subcutaneously in
the flank. Without further treatment, tumor outgrowth was
monitored and compared to untreated, naı̈ve mice. Untreated
mice showed comparable tumor outgrowth as seen in figure 3A
(upper left panel). The MIC long-term survivors all showed a
significant growth retardation following the tumor challenge
(figure 3C, upper and lower panel). These data show that the MIC
treatment had induced melanoma antigen-specific immunological
memory which remained effective at 65- and 165 days after
treatment cessation. Occasionally the development of vitiligo-like
patches of depigmented fur at sites distant from initial monoben-
zone application was found in about 50% of long-term surviving
mice (figure 3D). Importantly, vitiligo development occurred
exclusively in mice treated with MIC therapy, and was absent in
control-treated animals.
As summarized in table 1, the MIC regimen can mediate
significant tumor-growth delay and increase tumor-free survival.
Although monobenzone, CpG, imiquimod or the CI combination
induced significant melanoma growth inhibition, they did not
confer long-term tumor-free survival as found in the MIC therapy-
treated mice. Combined with the immunological data described in
figures 1 and 2, these results indicate that the immunological
impact of the MIC regimen translates to significant tumor
eradication in vivo.
Activation of an NK cell response in MIC treated mice in
vivo
We subsequently carried out immune monitoring of treated
mice to investigate the in vivo immune activation. We determined
the ratios of different peripheral blood leukocyte (PBL) populations
in blood obtained from the tailvein on day 8 and 23 following
melanoma inoculation (figure 4A). Interestingly, the MIC-treated
mice (right panels) showed increased levels of NK cells (NK1.1+
CD3-) among their PBL on day 8, as compared to the untreated
group. NK cell counts were also significantly increased in mice
treated with CpG, imiquimod or the combination of these
compounds (CI). Importantly, the increased NK cell numbers
only persisted up to day 23 in MIC-treated mice (figure 4A). This
MIC treatment-induced NK cell expansion has been found in
three independent experiments, the statistical analysis of which is
shown in table 2. Remarkably, monobenzone alone did not
influence PBL ratios at either time point. Taken together, although
the CI- and MIC treatment both mediated a significant increase in
blood NK cell counts, this effect persisted only in MIC-treated
mice.
Importantly, MIC-treated, tumor-free surviving mice included
in tumor challenge experiments (figure 3C) did not display
increased blood NK cell counts following the challenge (p.0.05;
unpaired t-test at day 15 following inoculation: average percentage
10 (+/2 1.4)). This indicates that the identified NK cell expansion
is MIC treatment-dependent. Furthermore, this suggests that the
protective immunological memory observed in figure 3C is not
dependent on NK cells. Instead, we found circulating melanoma
antigen-specific CD8+ T cells in the peripheral blood of these
MIC-treated, tumor-free surviving mice (figure 4B). To this end,
peripheral blood CD8+ T cells were tested for their recognition of
the H2-Kb/TRP-2180-188-antigen. This is an immunodominant
CD8+ T cell epitope of B16 melanoma. Figure 4B shows that a
significant population of TRP-2 antigen-specific CD8+ T cells is
present in tumor-free surviving mice, 120 days following the first
melanoma inoculation and 85 days after MIC treatment cessation.
Recognition of the control H2-Kb/OVA257-264-tetramer by
peripheral blood T cells of these mice was negative (data not
shown).
Taken together, these data demonstrate that the MIC treatment
effect is likely mediated by activated NK cells and CD8+ T cells.
Importantly, when treatment is stopped melanoma antigen-
specific CD8+ T cells remain active in tumor-free surviving mice,
suggesting that these T cells are responsible for the MIC therapy-
induced tumor protective immunological memory.
CD8+ T cell- and NK cell depletion prior to- and during
MIC therapy abrogates therapeutic effect
To verify whether NK cells and/or CD8+ T cells are essential
for the therapeutic effect of the MIC therapy, we performed MIC
treatment in C57BL/6 wildtype mice (n = 5/group) inoculated with
B16.F10 melanoma, following either a CD8+ T cell- or NK-cell
depleting pre-conditioning monoclonal antibody (mAb) regimen.
Control groups either received the MIC treatment following an
isotype control mAb regimen, or were left untreated. Depletion of
CD8+ T cells and NK-cells was confirmed to be .98% and
.95% respectively, as measured by flowcytometry (data not
shown).
Figure 2. A melanoma-reactive serum IgG response was found
in MIC-treated mice. Upon sacrifice peripheral blood serum was
obtained from treated mice, and serum antibody binding to B16.F10
melanoma cells was analyzed using flow cytometry (n = 5 mice per
group). EL4 syngeneic thymoma cells were used as a control to verify the
melanoma-specificity of the antibody binding, and showed comparable
serum IgG binding levels in all groups (p.0.05, one-way ANOVA). A
significant level of IgG antibody binding to the melanoma cells above the
EL4 background level was found in the MIC-treated mice (p,0.01, paired
t-test). Furthermore, only the MIC-treated mice showed melanoma-
reactive IgG levels significantly above those found in untreated mice
(p,0.02, unpaired t-test). IgA controls were negative, and IgM antibodies
showed no significant binding levels (data not shown). Data is
representative of three independent in vivo experiments.
doi:10.1371/journal.pone.0010626.g002
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Figure 3. Growth of subcutaneous melanoma is inhibited by MIC therapy. Mice (n = 7 per group) were treated with monobenzone, CpG,
imiquimod, CI- or the MIC-regimen. Tumor growth and animal survival were monitored for 200 days. Each graph line depicts an individual tumor
growth curve. A, Upper left panel: Untreated mice all show tumor development (TD) around day 10, and none of the mice experienced a 200-day
tumor-free survival (TFS). In contrast, 6 out of 7 MIC-treated mice remained tumor-free during treatment, and only one mouse showed delayed TD
MIC Therapy for Melanoma
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As shown in figure 5A, MIC treatment combined with CD8+ T
cell-depletion (red lines) resulted in melanoma development in
100% of the mice. In contrast, MIC-treated mice receiving isotype
control mAb (grey lines) showed reduced or no tumor outgrowth
comparable to previous experiments (table 1), while melanomas
grew out rapidly in untreated mice (black lines). Importantly, tumor
outgrowth for CD8+ T cell-depleted mice was significantly faster
than in mice treated with MIC therapy and the isotype control,
nonetheless still significantly slower than in untreated mice. These
results show that the anti-tumor effect of the MIC treatment was
largely abolished by the depletion of the CD8+ T cells. The minor
but significant tumor growth inhibition by the MIC regimen in the
absence of CD8+ T cells suggests that this therapy also effectively
involves another cell population, likely the NK cells we observed to
be activated in previous experiments. Figure 5B shows that
depletion of the NK cell population during MIC therapy resulted
in tumor development in 80% of the mice (green lines). Importantly,
melanoma outgrowth rapidly reached a state of ‘‘stable disease’’ in
Table 1. Statistics of in vivo tumor experiments.
Days after Average p-value
TFS during
treatment Median p-value TFS .100 days




) tumor size* (# mice) survival survival** (# mice)
(+/2 SEM) (vs. untreated) (% of group) (days) (% of group)
1 untreated 7 22 64.8 (14.3) nt 0 nt nt nt
monobenzone 7 22 27.1 (7.5) ,0.04 0 nt nt nt
MIC 7 22 3.1 (1.9) ,0.0011 4 (57%) nt nt nt
2 untreated 5 18 70.6 (18.0) nt 0 nt nt nt
monobenzone 5 18 50.0 (29.7) ns 0 nt nt nt
CpG 5 18 14.4 (3.5) ,0.02 0 nt nt nt
imiquimod 5 18 61.6 (7.2) ns 0 nt nt nt
CI 5 18 9.0 (4.5) ,0.02 0 nt nt nt
MIC 5 18 5.6 (3.0) ,0.008 2 (40%) nt nt nt
3 untreated 11 27 81.6 (20.2) nt 0 40 nt 0
MIC 11 27 0.4 (0.2) ,0.0006 8 (72%) .100 ,0.0001 7 (64%)
4 untreated 7 27 187.9 (13.4) nt 0 27 nt 0
monobenzone 7 27 88.9 (35.3) ,0.03 1 (14%) 34 ,0.03 1 (14%)
CpG 7 27 71.1 (30.0) ,0.004 0 35 ,0.005 0
imiquimod 7 27 102.9 (31.9) ,0.04 0 34 ,0.03 0
CI 7 27 13.0 (5.3) ,0.0001 1 (14%) 36 ,0.0003 1 (14%)
MIC 7 27 6.0 (6.0) ,0.0001 6 (85%) .200 ,0.0003 4 (57%)
ns: not significant (considered if p.0.05). Exp.: experiment.
nt: not tested. TFS: tumor-free survival.
*: Unpaired t-test. CI: CpG & imiquimod.
**: Logrank test for survival (endpoint tumor size max 200 mm2). MIC: monobenzone, imiquimod & CpG.
1:Day of tumor size comparison (last day on which experimental animals were all alive).
For Exp. 2 see Fig. 1A/B, for Exp. 3 see Fig. 3C (upper panel), for Exp. 4 see Fig. 3A/B and C (lower panel),
doi:10.1371/journal.pone.0010626.t001
during the treatment (lower right panel). *:10 days following treatment cessation at day 35, two additional mice developed a melanoma and these
animals were directly sacrificed for analysis without monitoring tumor growth kinetics. Eventually, 4 out of 7 MIC-treated mice showed 200-day TFS,
since 2 of the mice developed a melanoma 10 days following treatment cessation at day 35. The individual treatment components monobenzone,
CpG or imiquimod all mediated a certain degree of tumor-growth delay. Interestingly, CpG and imiquimod clearly work synergistically in the CI
regimen. Depicted tumor growth kinetics are representative of 4 independent in vivo experiments. For the statistical analysis of the in vivo tumor
growth kinetics of the treatments depicted in this figure, see table 1 (‘‘Exp. 4’’). B, Kaplan-Meier survival curve for the different treatment groups
depicted under A, showing 57% 200-day survival for MIC-treated mice against 14% long-term survival for monobenzone- or CI treated mice. Mice left
untreated or receiving one of the individual treatment components, no TFS was found. These animals were sacrificed around day 25–35 due to
maximally allowed tumor burden. C, The MIC therapy induced an effective immunological memory response. Upper panel: At day 100 (day 65 after
treatment cessation) surviving mice were challenged with a melanoma tumor-inoculation, and tumor growth was monitored without further
treatment. Untreated naive control mice showed rapid tumor development (black line, n = 7). Mice treated previously with MIC therapy showed
significant tumor growth delay (dashed line, n = 7). Lower panel: Mice challenged at day 200 (day 165 after treatment cessation) show protective
immunity to a comparable degree to that found in the day 100 tumor challenge shown in the upper panel. Untreated control mice showed normal
tumor development (black line, n = 7) while mice treated previously with the MIC therapy display significant tumor growth retardation (dashed line,
n = 4). Depicted graphs represent two independent tumor challenge experiments (follow-up on Exp. 3 & 4 in table 1). Statistical analysis using
unpaired t-test comparing MIC-treated mice with untreated animals on designated time points (*: p,0.04, **:p,0.01). D, MIC-treated, long-term
surviving mice occasionally develop progressively depigmenting patches of fur in a vitiligo-like pattern, distant from the initial monobenzone
application site (arrows). This effect occurs in approximately 50% of the long-term surviving animals.
doi:10.1371/journal.pone.0010626.g003
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this situation, with tumors remaining of equal size for extensive
periods of time. Taken together, these data imply that the MIC
therapy effectively engages both CD8+ T cells and NK cells in its
protective therapeutic effect.
MIC therapy significantly suppresses tumor growth of
established melanoma
To determine if MIC treatment has a therapeutic effect on
larger established melanoma, mice were subcutaneously inoculat-
ed with 16105 B16.F10 melanoma cells and treatments were
started when all tumors had reached the minimum measurable
size of 262 mm (on average after 3–4 days). Mice were treated
with the individual treatment compounds alone, or the CI- or
MIC regimen. Additionally, combinations of monobenzone with
either CpG or –imiquimod as only additional adjuvant were
compared with the CI regimen to verify if monobenzone is the
critical component in the MIC therapy. The statistical analyses of
the tumor growth kinetics in 4 independent in vivo experiments
using this established tumor setting are summarized in table 3. All
treatments containing monobenzone and at least one adjuvant
mediated a significant growth delay of established B16.F10
tumors, whereas the adjuvants imiquimod and CpG alone or
combined (CI) did not significantly inhibit tumor growth. Of the
treatments containing monobenzone, the combination of all three
compounds (MIC treatment) showed the most profound thera-
peutic effect. Importantly, as shown in table 3 under ‘‘Exp. 5’’,
monobenzone combined with either imiquimod or CpG as
adjuvants displayed a significantly better therapeutic effect than
the CI regimen, when compared to untreated mice. Both exp. 5
and exp. 6 showed that MIC treatment was significantly more
effective than CI treatment. This indicates monobenzone to be the
pivotal component in mediating the therapeutic effect of the MIC
regimen. Besides significantly suppressing tumor growth, MIC
therapy was also found to significantly improve the survival of
mice bearing established melanoma.
These data illustrate that the MIC regimen also has a significant
therapeutic effect in the treatment of established subcutaneous
melanoma.
Discussion
In the present study we demonstrate that the vitiligo-inducing
properties of monobenzone cream combined with the immunos-
timulatory adjuvants CpG and imiquimod synergistically induces
potent melanoma antigen-specific immunity and tumor eradica-
tion in the B16-B6 mouse model of melanoma. We show that the
MIC treatment of subcutaneous B16.F10 melanoma in C57BL/6
wildtype mice inhibited the outgrowth of melanoma in up to 85% of
the mice. Moreover, 64% or 57% of the mice remained tumor-
Figure 4. MIC-treated mice show a sustained NK cell expansion and circulating melanocyte antigen-specific CD8+ T cells. A,
Peripheral blood was collected from the tailvein of treated mice on day 8 and 23 of treatment, and average ratios between T cells (CD3+, black
sections), B cells (CD19+, white sections), NK cells (NK1.1+, CD3-, grey sections) and other peripheral blood leukocytes (PBL; dashed sections) were
determined for the PBL (n = 7 mice per group). Interestingly, MIC-treated mice showed a significant NK cell expansion on both day 8 and 23 (see
table 2, ‘‘Exp. 4’’). This expansion of NK cells was also found in CpG-, imiquimod- and CI-treated mice, although for these animals this reaction was
only found on day 8. Monobenzone alone did not influence PBL ratios on either time point, comparable to untreated mice. Depicted data is
representative of three independent in vivo mouse experiments. For the statistical analysis of the in vivo differences in NK cell counts in these
experiments see table 2. B, Peripheral blood CD8+ T cells were tested for binding to H2-Kb/TRP-2180-188-tetramers at day 120 following tumor
inoculation (day 85 after treatment cessation, n = 4). TRP-2 represents one of the immunodominant epitopes of B16.F10 melanoma. Long-term
surviving, MIC-treated mice showed a significant population of TRP-2-specific CD8+ T cells circulating in their peripheral blood at day 120, as
compared to untreated mice 10 days after tumor inoculation (n = 7). Binding to control H2-Kb/OVA257-264-tetramer by the tested PBL was negative
(data not shown).
doi:10.1371/journal.pone.0010626.g004
MIC Therapy for Melanoma
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10626
free for more than 100- or 200 days respectively. The MIC
treatment induced melanoma antigen-specific immunological
memory, effectively suppressing tumor growth up to 165 days
after treatment cessation. Immunomonitoring of the MIC treated
mice showed that the regimen induced a systemic B16-specific
CD8+ T cell- and NK cell response. Additionally, a melanoma-
specific serum IgG response was found in the MIC treated mice.
MIC therapy was also effective against larger established tumors,
mediating significant tumor growth inhibition and prolonged
survival. These data show that MIC therapy triggers a strong
melanoma-specific in vivo innate- and adaptive immune response.
It has been suggested by Berghöfer et al. that the combination
imiquimod and CpG is deleterious, since in vitro it has been found
that triggering of TLR7 and TLR9 simultaneously on DC or
leukocytes will deteriorate the induced interferon-a production by
these cells [37]. Importantly, the study by Berghöfer et al.
concludes that the inhibitory effect of simultaneous TLR7 and -
9 triggering only applies to CpG types A and C, while such an
effect was not found for CpG type B. Our present study employs
CpG 1826, which is a B-type CpG. While Berghöfer et al. show
that combining B-type CpG with TLR7 triggering was not
inhibitory, even showing a slight synergistic trend, we have
actually found a functional synergism between CpG 1826 and
TLR7-triggering by imiquimod in our present in vivo study.
Depletion of CD8+ T cells and NK cells prior to- and during
MIC treatment ablated the therapeutic effect, indicating that these
cells are imperative in mediating the MIC therapeutic effect. It
seems that MIC therapy induces the immune cascade as
previously suggested by Liu et al. [38], which is characterized by
the sequential activation of NK cells, conventional DC and
ultimately the formation of effective CD8+ T cell immunity and
immunological memory. Importantly, MIC treatment also led to
the generation of melanoma-specific antibodies. These antibodies
bound to intracellular antigens, selectively in melanoma cells. This
indicates they are directed against antigens in the melanosome, an
organelle found exclusively in pigmented cells such as melanocytes
and melanoma cells. Since the melanosome is the primary source
of melanocyte differentiation antigens, the antibodies we identified
can enhance the adaptive immune response through opsonisation
of antigen liberated from dying pigmented cells. Through the
subsequent formation of immune complexes this improves the
uptake and successive (cross) presentation of melanoma antigens
by DC [39].
Melanoma-specific CD8+ T cells induced by the MIC regimen
show a higher functional avidity. As shown in figure 1A, CD8+ T
cells in the MIC-treated mice could be activated by non-IFN-c-
primed melanoma cells. These cells have very low levels of MHC
class-I (figure 1C), rendering them poorly recognizable to T cells.
The occurrence of high avidity T cells recognizing poorly
immunogenic melanoma cells suggests that the MIC therapy
mediates an avidity maturation process, which is known to occur
in T cell populations exposed to constant high levels of antigen
[40]. The continuous application of monobenzone on the skin may
generate a steady flow of melanocyte-specific antigens, leading to
the avidity maturation of the reactive T cell pool. This maturation
clearly did not occur during the CI treatment, thereby leading to
the absence of high avidity T cells recognizing IFN-c unprimed
melanoma cells in these mice. The CI regimen provides a general
immune activating stimulus, which in the presence of melanoma
may result in short-term anti-melanoma reactivity. In contrast, the
MIC regimen specifically engages melanocyte differentiation
antigens in the generation of adaptive immunity via the
monobenzone component (discussed below). The therapeutic
value of this antigen-targeting by monobenzone is demonstrated
by the enhanced ability to induce melanoma-reactive CD8+ T
cells and protective anti-melanoma immunity in vivo, as compared
to the CI regimen.
Concerning the working mechanism of monobenzone, it has a
selective- and inactivating interaction with the enzyme tyrosinase
which catalyzes pigment synthesis in the melanosome, an organelle
exclusively found in melanocytes [21]. This interaction results in
the formation of quinone metabolites which bind to cysteine
residues in the protein peptide chain, forming quinone-haptens
[31]. These quinone hapten-carrier complexes are known to be
potent contact sensitizers which can trigger hapten-specific
immune responses [41,42]. Generally, this kind of hapten-induced
immunity results in enhanced depigmentation in vivo, since
quinone-metabolites of phenols and catechols are known to
induce more extensive depigmentation than the parental com-
pound [33]. Moreover, the extent of catechol-induced depigmen-
tation depends on quinone formation by the tyrosinase enzyme,
including subsequent covalent binding of the quinone to proteins
[32]. At high concentrations (250–500 mM for 24 hours) mono-
benzone can additionally induce non-apoptotic cell death in
exposed melanocytes in vitro [43]. In contrast, we have investigated
Table 2. Statistics of in vivo peripheral blood NK cell counts.
Days after average %




2 untreated 5 15 7.3 (0.4) nt
monobenzone 5 15 6.3 (0.2) ns
CpG 5 15 8.2 (1.1) ns
imiquimod 5 15 8.2 (0.3) ns
CI 5 15 12.3 (1.9) ,0.04
MIC 5 15 13.3 (2.2) ,0.03
4 untreated 7 8 6.65 (0.7) nt
monobenzone 7 8 5.91 (0.2) ns
CpG 7 8 11.42 (1.5) ,0.02
imiquimod 7 8 9.91 (0.7) ,0.01
CI 7 8 17.29 (1.0) ,0.0001
MIC 7 8 17.43 (1.6) ,0.0001
untreated 7 23 8.38 (1.2) nt
monobenzone 7 23 7.03 (0.7) ns
CpG 7 23 6.17 (0.7) ns
imiquimod 7 23 3.81 (0.1) ns
CI 7 23 5.95 (0.5) ns
MIC 7 23 13.74 (0.7) ,0.01
7 untreated 7 2 6.7 (0.4) nt
MIC 7 2 16.6 (2.2) ,0.001
untreated 7 8 4.9 (0.3) nt
MIC 7 8 12.6 (1.1) ,0.0001
untreated 7 15 5.9 (0.8) nt
MIC 7 15 12.8 (0.3) ,0.002
Exp.: experiment. CI: CpG, imiquimod.
nt: not tested. MIC: monobenzone, imiquimod & CpG.
ns: not significant (considered if p.0.05). For Exp. 4 see Fig. 4A.
*: Unpaired t-test.
1:Day after tumor inoculation on which PBL were tested.
doi:10.1371/journal.pone.0010626.t002
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that at lower concentrations (20 to 40 mM) monobenzone-exposed
pigmented cells provoke robust and specific CD8+ T cell
immunity, by the formation of quinone-haptens to the tyrosinase
protein and the subsequent activation of local dendritic cells by
exposed pigmented cells (Van den Boorn et al., manuscript in
preparation of submission). Since melanoma cells share many antigens
with their normal counterparts, the melanocytes, the melanocyte-
specific immunity evoked by monobenzone also acts against
melanoma cells (as evidenced by the MIC therapy). Because
priming of the anti-melanoma immune response during MIC
therapy depends upon the interaction of monobenzone with
tyrosinase in skin melanocytes, and the induced immune response
encompasses more melanosomal antigens besides tyrosinase
(figure 4B and manuscript in preparation), our MIC regimen may
well be effective against tyrosinase-negative melanoma variants.
Moreover, tyrosinase expression appears to be conserved in
malignant melanoma cells [44]. Tyrosinase expression in mela-
noma tissue also provides the possibility of local treatment of
cutaneous metastasis with the MIC regimen.
Interestingly, vitiligo-like depigmentation of the fur distant from
the monobenzone application site occurred in approximately 50%
of the long-term surviving MIC-treated animals (figure 3D), but
not in non-responding or control treated mice. This phenomenon
illustrates an enduring systemic immune response effective against
pigmented cells. However, vitiligo development was expected to
directly correlate with the effective anti-tumor immune response
observed in all MIC –treated mice, especially since monobenzone
is a potent skin depigmenting agent in humans. The vitiligo-like
fur depigmentation in mice depends on autoimmune melanocyte
destruction in the hair follicle. The modest level of vitiligo may be
explained by the fact that hair depigmentation (poliosis) only
occurs in advanced cases of vitiligo [45], and is likely related to the
hair follicle being an immune-privileged site in both humans [46]
and mice [47]. Thereby, fur depigmentation likely underestimates
the level of autoimmune activation against pigmented cells. The
immune privilege of the hair follicle can thereby explain the
modest depigmentation observed in the MIC-treated mice.
In conclusion, we have developed a new form of off-the-shelf
melanoma immunotherapy consisting of two creams and four
CpG injections. This simple design makes the MIC therapy easily
applicable in the clinic. Moreover, this low-cost regimen does not
require stringent patient eligibility criteria such as HLA-haplotype,
Figure 5. The therapeutic effect of MIC therapy is abrogated by NK cell- or CD8+ T cell depletion. Each graph line represents an
individual tumor growth curve. A, Mice depleted of CD8+ T cells prior to tumor inoculation and throughout the MIC therapy (red lines, n = 5) all
developed a tumor. In these MIC-treated mice tumors grew out significantly faster than in the isotype-control mAb-treated mice (grey lines; p,0.02,
n = 5), who displayed tumor growth kinetics similar to MIC-treated animals in previous experiments. Nonetheless, tumor outgrowth in CD8+ T cell
depleted mice was still significantly slower than in untreated mice (black lines; p,0.02, n = 5). The tumor size of CD8+ T cell depleted animals was
statistically compared with isotype-control mAb-treated animals on day 28, and with untreated animals on day 22. B, Mice depleted of NK cells prior
to tumor inoculation and throughout MIC therapy (green lines, n = 5) showed tumor establishment in 80% of mice. Tumors in these mice grew out
very slowly or remained of equal small size throughout the experiment. In contrast, untreated mice showed rapid tumor development (black lines,
n = 5). Mice treated with isotype-control mAb and MIC therapy (grey lines, n = 5) showed tumor growth similar to mice treated with MIC therapy in
previous experiments.
doi:10.1371/journal.pone.0010626.g005
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and does not require elaborate patient-specific in vitro cell cultures
or non-myeloablative lymphodepletion prior to the start of
treatment, reducing patient treatment strain.
Materials and Methods
Ethics statement
All animal experiments were carried out under protocols
approved by the Animal Ethical Committee of the Academic
Medical Centre in Amsterdam (DEC code DDE, studies 100452,
100969 and 101291). Mice were obtained from Charles River
Labs (Maastricht, The Netherlands). Animals were housed in the
Animal Research Institute Amsterdam (ARIA; ABSL-3/DM-II
housing level) and cared for by qualified personnel on a daily basis.
Food and water were available ad libitum and cages contained
bedding, shelter and nesting material.
Cell lines and mice
B16.F10 melanoma cells (a kind gift from Dr. A. Jorritsma,
Netherlands Cancer Institute, Amsterdam, The Netherlands) and
EL4 thymoma cells (a kind gift from the department of
Immunohematology and Blood Transfusion, Leiden University
Medical Center, Leiden, The Netherlands) were maintained in
culture medium consisting of RPMI 1640 (Cambrex bioscience,
Verviers, Belgium) with 10% heat-inactivated fetal bovine serum
(Hyclone, Erembodegem-Aalst, Belgium), 2 mM L-glutamine
(Gibco invitrogen, Breda, The Netherlands), 50 U ml21 penicillin
and 50 mg ml21 streptomycin (Gibco invitrogen), in a humidified
atmosphere at 37uC and 5% CO2. Female SPF C57BL/6 wildtype
mice were used in tumor experiments at 10 weeks of age.
Tumor inoculation and treatments
Mice were inoculated with 2.56103 or 16105 B16.F10
melanoma cells in 50 ml of sterile PBS (Dulbecco’s PBS, PAA,
Pasching, Austria) subcutaneously in the right flank. Treatments
were started 2 days later (for 2.56103 inoculated melanoma cells)
or when all tumors reached a minimum size of 262 mm (for
16105 inoculated melanoma cells on average after 3–4 days).
Treatment continued for 33 days. B16.F10 in vitro cell culture was
standardized for all experiments. Melanoma cells were in the
exponential growth phase in vitro when used for in vivo inoculation,
and were confirmed to be .98% viable by trypan blue exclusion.
Daily, perpendicular tumor diameters were measured using
callipers. Mice were treated with daily applications of 50 ml of
20% monobenzone cream (4-benzyloxyphenol, Sigma-Aldrich,
Zwijndrecht, The Netherlands; cream prepared by the Academic
Medical Centre pharmacy for use in animal experiments) and/or
50 ml of 5% imiquimod cream (AldaraTM, 3 M Healthcare,
Leicestershire, UK) on Monday, Wednesday and Friday on the
shaved abdomen. Creams were completely massaged in using a
spatula. Mice received 50 ml of completely phosphorothioated
CpG oligodeoxynucleotides (1 mg ml21 in sterile PBS) injected
peritumorally on day 0, 3, 6 and 21 (CpG B 1826, 59-
TCCATGACGTTCCTGACGTT-39, produced as reported pre-
viously [48]).
Table 3. Statistics of in vivo tumor experiments inoculating 1610e5 melanoma cells and starting treatment when all tumors were
at least 262 mm.
Days after Average p-value p-value Median p-value
Exp. Treatment # mice inoculation
1
tumor size (mm2) tumor size* tumor size* survival survival**
(+/2 SEM) (vs. untreated) (vs. CI) (days)
5 untreated 5 15 98.6 (20.7) nt nt 15 nt
monobenzone 5 15 73.6 (10.2) ns nt 15 ns
imiquimod 5 15 74.4 (5.0) ns nt 15 ns
CpG 5 15 55.0 (5.6) ns nt 19 ,0.05
CI 5 15 57.8 (8.0) ns nt 19 ,0.05
monobenzone, imiquimod 5 15 32.4 (10.3) ,0.03 ns 19 ,0.05
monobenzone, CpG 5 15 32.8 (9.6) ,0.03 ns 22 ,0.02
MIC 5 15 26.4 (7.5) ,0.02 ,0.03 22 ,0.02
6 untreated 3 10 81.3 (29.4) nt nt 13 nt
CI 5 10 1.4 (0.2) ,0.01 nt 28 ,0.007
MIC 5 10 1.0 (0.3) ,0.01 ,0.04 24 ,0.007
7 untreated 7 16 135.6 (24.4) nt nt 18 nt
MIC 7 16 8.9 (3.1) ,0.001 nt 28 ,0.002
8 untreated 7 16 145.4 (15.1) nt nt 16 nt
MIC 7 16 17.6 (6.3) ,0.0001 nt 26 ,0.0001
ns: not significant (considered if p.0.05).
nt: not tested.
1:Day of tumor size comparison (last day on which experimental animals were all alive).
*: Unpaired t-test.




MIC: monobenzone, imiquimod & CpG.
doi:10.1371/journal.pone.0010626.t003
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In vitro splenocyte priming assay
Erythrocytes were removed from fresh splenocyte single cell
suspensions by hypotonic lysis, and splenocytes were cultured in
RPMI 1640 (Cambrex) with 10% heat-inactivated fetal bovine
serum (Hyclone), 2 mM L-glutamine (Gibco invitrogen),
50 U ml21 penicillin and 50 mg ml21 streptomycin (Gibco
invitrogen), 50 mM 2-mercaptoethanol (Sigma-Aldrich, Zwijn-
drecht, The Netherlands), 15 mg ml21 gentamycin (Duchefa,
Haarlem, The Netherlands), 20 U ml21 IL-2 (Novartis, Arnhem,
The Netherlands) and 5 mg ml21 ConA (Boehringer Mannheim,
Mannheim, Germany). ConA blasts were co-cultured on day 10
with B16.F10 and EL4 cells in vitro in a 1:1 ratio, in culture
medium supplemented with IL-2 and 2-mercaptoethanol for
5 hours at 37uC and 5% CO2 in the presence of brefeldin-A
(1:1000, Golgiplug, BD Bioscience, San Diego, CA) protein
transport inhibitor. When applicable B16.F10 cells were 24 hours
IFN-c pre-treated prior to splenocyte co-culture (1000 U ml21,
Strathmann, Bergisch Gladbach, Germany). Subsequently cells
were stained for intracellular cytokine production.
Flow cytometry and intracellular cytokine staining
Erythrocyte-free single cell suspensions of splenocytes, ConA
blasts or PBL were prepared in FACS buffer (PBS with 1% bovine
serum albumin and 0.05% NaN3) and cells were stained in the
dark on ice for 20 minutes for surface expression of CD8a (APC-
Cy7), CD4 (PerCP-Cy5.5), CD3e (FITC), CD137 (FITC), CD19
(PerCP-Cy5.5), or NK1.1 (Pe-Cy7; all antibodies BD Bioscience,
San Diego, CA). For intracellular staining, cells were permeabi-
lized using the Cytofix/Cytoperm kit (BD Bioscience) according to
the manufacturer’s protocol, and stained for intracellular cytokines
using TNF-a (Pe-Cy7, BD Bioscience), TNF-a (PE, e-Bioscience,
San Diego, CA) or IFN-c (Alexa-700, BD Bioscience). Tetramer
analysis was performed by incubating cell suspensions with H2-
Kb/TRP-2180-188-tetramer (SVYDFFVWL, APC-labelled, San-
quin, Amsterdam, The Netherlands) or H2-Kb/OVA257-264-
tetramer (SIINFEKL, PE-labelled, kind gift from K.L. Franken,
Leiden University Medical Centre, The Netherlands) in CM for
25 minutes at 37uC and 5% CO2 prior to subsequent surface
antibody staining. Surface MHC class-I detection was performed
by incubating IFN-c-primed and –unexposed B16.F10 cells with
mouse-anti-mouse MHC class-I antibody (clone 28-14-8, IgG2a,
eBioscience, San Diego, CA) followed by incubation with goat-
anti-mouse IgG2a-detecting antibody (Alexa 488, Molecular
Probes, Invitrogen, Breda, The Netherlands). Samples were
measured on a FACS Canto-II flowcytometer (Beckton Dickinson,
San Diego, CA). Data was analyzed using FlowJo software (Tree
Star Inc., Ashland, OR).
Serum antibody determination
B16.F10 and EL4 cells were washed in FACS buffer and
permeabilized using the Cytofix/Cytoperm kit (BD Bioscience,
San Diego, CA) according to the manufacturer’s protocol. Cells
were incubated with mouse serum diluted 1:200 in Perm/Wash
(BD Bioscience) for 1 hour at room temperature. Subsequently,
cells were tested for serum-antibody binding by incubation with
biotinylated anti-mouse IgG, -IgA and -IgM antibodies (Biole-
gend, Uithoorn, The Netherlands) for 20 minutes on ice. Binding
of biotinylated detection antibodies to target cells was detected by
incubation with streptavidin-APC (BD Pharmingen, San Diego,
CA) for 20 minutes in the dark on ice, and analyzed by a FACS
Canto-II flowcytometer (Beckton Dickinson, San Diego, CA).
In vivo NK cell- and CD8+ T cell depletion
Mice were injected intraperitoneally on day -2 and 0 prior to
tumor inoculation and every following fourth day during the
experiment with 100 mg of anti-mouse CD8a or anti-mouse
NK1.1 (clone 53-6.7 or PK136 respectively, low-endotoxin azide-
free purified, Biolegend, Uithoorn, The Netherlands) or IgG2a k
isotype control (clone RTK2758, low-endotoxin azide-free
purified, Biolegend) monoclonal antibodies. Prior to tumor
inoculation CD8+ T cell or NK cell depletion was confirmed by
flowcytometry.
Statistical analysis
Analysis comparing values between treatment groups were
performed using a two-tailed unpaired t-test (95% CI). Different
conditions within the same treatment group were compared using
the two-tailed paired t-test (95% CI). Survival data was analysed
using the Logrank test (95% CI). *: p,0.04, **: p,0.01. Analyses
carried out with GraphPad Prism 5 software (GraphPad, La Jolla,
CA). Graphs depict mean with SEM.
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